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Lymphomas are malignancies of the lymphoid tissue. They are divided in Hodgkin’s Lym-
phoma (HL) and Non-Hodgkin’s Lymphoma (NHL). Whereas HL is a relatively homogenous 
disease, NHL encompasses around 60 different entities, each with its own clinical presenta-
tion, morphology, treatment and prognosis. Burkitt lymphoma (BL) is the most aggressive 
form of NHL with a doubling time of about 24 hours. While it is relatively rare in adults, 
it is the most common type of NHL in children. Diffuse large B-cell lymphoma (DLBCL) is 
a closely related type of NHL. It is the most common type of NHL seen in adult patients 
and the second most common in children. While BL is considered a homogeneous disease, 
DLBCL shows clear clinical, morphological and biologic heterogeneity. A subset of DLBCL 
cases shares features with BL. The choice between a diagnosis of BL or DLBCL for such cases 
is hard to make, while it has important clinical consequences concerning treatment and 
prognosis. In this thesis we defined a molecular profile for BL and then tried to answer the 
question whether these “gray-zone” cases should be considered as BL, DLBCL or deserve 
their own diagnostic entity. In this chapter a general introduction on BL and the diagnostic 
dilemma with these “gray-zone” cases is given.
The discovery of Burkitt lymphoma
BL was first described in 1958 by the British surgeon Denis P Burkitt as a sarcoma pre-
senting either in the jaw or the abdomen of African children.1 In 1960 O’Conor and Davies 
described this lesion as a type of lymphoma instead of sarcoma.2 The first ideas on the 
pathogenesis of the disease came from an epidemiological study. During a 100 day safari in 
1961, Burkitt observed a relationship between the incidence of BL and certain geographic 
and climatic factors,3 which later appeared to match the distribution of malaria falcipar-
um.4 Three years later Epstein and colleagues discovered the Epstein-Barr virus (EBV) in 
a large number of endemic BL cases and suggested a causative role for the virus in the 
pathogenesis of this lymphoma.5 However, the common presence of EBV infection ruled 
against its role as a single cause for the lymphoma. Neither could the co-occurrence with 
malaria, which provided either a hyperplastic or immunodeficient environment, fully explain 
its pathogenesis.6 
New input in the pathogenesis of the disease came from a genetic point of view. In 1972 
Manolov and Manolova described a recurring genetic abnormality in BL cell lines involving 
an extra band on the telomeric end of the long arm of chromosome 14.7 Although several 
groups found that the telomeric region of the long arm of chromosome 8q translocated 
towards specific bands on chromosome 2, 14 or 22 in both endemic and sporadic BL cases 
during the following years,8-13 it was not before 1981 that the oncogene MYC was discov-
ered to be the target of the recurrent translocations.14,15 In the following years it became 
clear that MYC overexpression played an pivotal role in BL, but that additional oncogenic 
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events were needed for the development of BL, as MYC overexpression alone is not suf-
ficient for tumorgenesis.16,17
The clinical variants of Burkitt lymphoma  have their own epidemiology 
and clinical presentation
Three distinct clinical variants of BL are observed: the endemic, the sporadic and the 
immunodeficiency-related variant (Table 1).18 The endemic variant, occurring in equatorial 
Africa and Papua-New Guinea, represents the most common form of pediatric lymphoma 
in these regions. It normally presents with a large extranodal mass either in the jaw or the 
abdomen in children around the age of 5, preferably males. It is rarely seen in adults. Inci-
dence rates in children are around 1:10,00019 with a male:female ratio of about 2.5:1.20,21 
There is a high association with EBV with over 95% of the cases being positive for EBV.22 
Epidemiological studies have also described a relationship with malaria infection4,6 and ex-
posure to a certain type of domestic bush, Euphorbia Tirucalli.23 
The sporadic variant occurs throughout the world, mainly in children and young adults. 
Incidence rates are much lower (2.5:1,000,000), but with a similar male:female ratio of 
2.5:1. It usually presents with an abdominal mass, most often originating from the ileocecal 
region. Other common locations are the ovaries, kidneys or breasts. Lymph node involve-
ment is more often seen in adults. Bone marrow involvement and/or leukemia are only seen 
in cases with extensive disease. In contrast with endemic BL, EBV is only seen in a minority 
of sporadic cases (15-20%).24 
The immunodeficiency-related variant is most commonly associated with the Human Im-
munodeficiency Virus (HIV) and often represents one of the first AIDS defining symptoms. 
BL is only rarely seen in the context of other immunodeficiency states (e.g. as post-trans-
plant lymphoproliferative disease, PTLD). Incidence rates of the immunodeficiency-related 
variant vary between 2:1,000 in children with AIDS25 and 1:1,000 in adult AIDS patients,26 
with a male:female ratio of 2:1. In contrast with the other two variants, nodal presentation 
as well as bone marrow involvement is relatively common. EBV is identified in 25-40% of 
HIV associated BL cases.
WHo criteria for morphology and immunophenotype of Burkitt lymphoma
Although it has carried a number of different names throughout the years and dif-
ferent lymphoma classifications (Table 2), BL has always been considered a separate and 
unique entity. According to the morphological criteria of the 2001 World Health Organiza-
tion (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues,18 classic BL 
cases (most endemic and the majority of the sporadic cases) show a monotonous, cohesive 
growth pattern. The tumor cells are medium-sized (the nuclei are about the same size as the 
tingible body macrophages) and have a strong basophilic cytoplasm. The nuclei are round 









Table 1. Characterization of the three clinical variants of Burkitt lymphoma.
Criteria endemic BL sporadic BL immunodeficiency / AIDS 
related BL
Age and gender Mostly young boys Bimodal age distribution, with 
a peak at 5-10, mostly boys 
and rise after the age of 60, 
both male and female
Adolescents / adults
Kinetics Rapidly growing, bulky Rapidly growing, bulky Rapidly growing, bulky
Primary presentation Jaw >> ileocecal / 
mesenteric, ovary, kidney, 
breasts
Ileocecal / mesenteric, ovary, 
kidney, breasts; in adults more 
nodal
Mostly nodal, CNS
Primary leukemia Not Primary type of ALL-L3 (FAB 
classification)




CNS CNS, may become leukemic CNS, may become leukemic, 
extensive dissemination
Histology, low power Cohesive, starry sky, 
apoptosis may be abundant, 
few residual lymphocytes
Cohesive, starry sky, apoptosis 
may be abundant, few residual 
lymphocytes
Cohesive, starry sky, apoptosis 




Medium sized, round nuclei, 
equal or smaller than of 
macrophages (in atypical 
BL some variation is size 
and contour), granular 
chromatin, multiple medium 
sized nucleoli, or (atypical) 
less and more larger nucleoli; 
basophilic cytoplasm, often 
containing many lipid 
droplets
Medium sized, round nuclei, 
equal or smaller than of 
macrophages (in atypical BL 
some variation is size and 
contour), granular chromatin, 
multiple medium sized nucleoli, 
or (atypical) less and more 
larger nucleoli; basophilic 
cytoplasm, often containing 
many lipid droplets
Medium sized, round nuclei, 
equal or smaller than of 
macrophages (in atypical BL 
some variation is size and 
contour), granular chromatin, 
multiple medium sized nucleoli, 
or (atypical) less and more 
larger nucleoli; basophilic 
cytoplasm, often containing 
many lipid droplets; may be 
more abundant (plasmacytic 
differentiation)
Immunophenotype sIgM+, IgD-, k+/l+, CD20+, 
CD10+, bcl6+, bcl2-,  
TdT-, Ki-67/MIB-1 >95%, 
other features less well 
known
sIgM+, IgD-, k+/l+, CD20+, 
CD10+, bcl+, bcl2-, TdT-, 
MUM1- or weak, CD38+, 
CD77+, CD138-, TCL1+, 
CD44-, Ki-67/MIB-1 >95%; 
rare cases may be CD5+
SIgM+ and often also cIgM+, 
IgD-, k+/l+, CD20+, CD10+, 
bcl6+, bcl2-, TdT-, MUM1- or 
weak, CD38+, CD138-, TCL1+, 
CD44-, Ki-67/MIB-1 >95%
Genetic t(8;14)(q24;q32),  t(8;22)
(q24;q11) or t(2;8)(p11;q24) 
in 90-100%
t(8;14)(q24;q32) in 80-85%,  
t(8;22)(q24;q11) in 10-15%, or 
t(2;8)(p11;q24) in 5%
t(8;14)(q24;q32) in 80-85%,  
t(8;22)(q24;q11) in 10-15%, or 
t(2;8)(p11;q24) in 5%
MYC and IGH 
breakpoints
8q24: breakpoints more 
often far upstream of MYC; 
IGH breakpoints more often 
at VDJ region (mediated by 
somatic mutations) 
8q24: breakpoints more often 
directly upstream of MYC or 
in intron 1; IGH breakpoints 
more often at switch sites 
(variable, also downstream of 
Sµ) mediated by class switch 
recombination
8q24: breakpoints more often 
directly upstream of MYC or 
in intron 1; IGH breakpoints 
more often at switch sites 
(variable, also downstream of 




therefore many mitotic figures can be observed. The rate of apoptosis is also very high, 
resulting in a so-called “starry-sky”-like appearance caused by the multiple macrophages 
that have phagocytized the apoptotic debris.
Two morphologic variants are described in the WHO classification. First, the atypical BL 
variant (aBL; sometimes also called Burkitt-like lymphoma - BLL) shows greater pleomor-
phism in nuclear size and shape compared with classic BL. In addition, nucleoli are less 
numerous and more prominent. For the diagnosis a growth fraction of or close to 100% 
(as determined by the Ki-67/MIB-1 labeling index) and a proven or strongly suspected MYC 
translocation are required. Secondly, the plasmacytoid variant is often seen in immunode-
ficiency related cases of BL, with eccentric cytoplasm and often a single, centrally located 
nucleolus. A certain degree of pleomorphism may also be observed, just as in the atypical 
variant.
All BL cells should express surface IgM, pan-B cell antigens, including CD19, CD20, 
CD22 and CD79 and the germinal center markers CD10 and bcl6. The cells should be nega-
tive for CD5, CD23, CD138, bcl2 and terminal deoxynucleotidyl transferase (TdT). The very 
high proliferation index is represented by a Ki-67/MIB-1 staining of close to 100% of cells.




High, not ongoing, possibly 
antigen selection
Intermediate, not ongoing, no 
evidence of antigen selection




In 40% no other 
abnormalities. Limited data 
available
In 40% no other abnormalities. 
Gains: 1q, 7, and 12; losses:  
6q, 17p, 13q32-q34
Not different from sBL 
Epstein Barr virus >95%; latency type I 
(EBNA1, EBER)
15-20%; latency type I (EBNA1, 
EBER)
25-40%; latency type I (EBNA1, 
EBER); associated with relatively 
high counts of CD4+ cells
Table 1 continued
Table 2. Burkitt lymphoma throughout the different lymphoma classifications.
Classification Introduced in Name
Rappaport 1966 Undifferentiated lymphoma, Burkitt type
Lukes-Collins 1974 Small non-cleaved follicular centre cell lymphoma
Kiel 1974 Burkitt lymphoma
Working Formulation 1982 Small non-cleaved lymphoma, Burkitt type
Updated Kiel 1988 Burkitt lymphoma
REAL 1994 Burkitt lymphoma








1a MYC translocation is the genetic hallmark of Burkitt lymphoma
The genetic hallmark of BL is translocation of the MYC gene (located at cytoband 8q24) 
towards one of the immunoglobulin (IG) loci. Such a translocation is the prerequisite for 
the diagnosis of BL and therefore should be present in all cases of BL.18 The typical t(8;14)
(q24;q32) translocation juxtaposes the MYC gene to the immunoglobulin heavy chain lo-
cus, which occurs in approximately 80% of BL patients, whereas the variant t(2;8)(p11;q24) 
and t(8;22)(q24;q11) translocations involve the kappa and lambda immunoglobulin light 
chain loci in about 5% and 15% of BL, respectively. All three translocations result in consti-
tutive over-expression of MYC.
These translocations are regarded as aberrant products of the immunoglobulin diver-
sification process. In B-cells V(D)J recombination, somatic hypermutation (SHM) and class 
switch recombination (CSR) allow the production of antibodies with an almost unlimited 
diversity (Figure 1). As these mechanisms involve double-strand DNA breaks, mistakes can 
easily lead to translocation events, especially when another double-strand break is nearby. 
Based on the location of the breakpoints in the IgH locus at either the IgH switch regions 
or within or downstream of rearranged V genes, aberrant CSR and SHM are regarded as 
the main causes of an IG-MYC breakpoint in BL.27 Recently, activation-induced cytidine 
deaminase (AID) was described to have an important role in both CSR and SHM and the 
translocation process.28 It is also thought that AID mistargets MYC in a process of parallel 
CSR and in this way facilitates the translocation event.28,29
V(D)J recombination Class switch recombination Somatic hypermutation
figure 1. antibody diversification through V(D)J recombination, class switch recombination 
(Csr) and somatic hypermutation (sHM).
V(D)J recombination (left) involves the variable regions and occurs in two steps. In the first rearrangement, 
a D gene segment is rearranged to a J segment, forming a DJ joint. In the second rearrangement, a V 
segment is rearrranged to a DJH joint, forming a VDJ joint. Which VDJ segements are joined determines 
the specificity of the antibody. In the human IgH locus on chromosome 14, there are about 50 functional 
V, 27 D and 6 J gene segments. In class switch recombination (middle), the expressed heavy chain 
constant region (C) gene is  replaced by a downstream C gene. The recombination process involves 
deletion of the DNA between repetitive DNA regions (switch regions, sμ, sγ and sα) upstream of the 
recombining C genes. The specificity of the antibody remains unaltered, but the effector functions of the 
antigen receptor are changed. Somatic hypermutation (right) introduces point mutations and also some 
deletions and duplications specifically into the V region genes and flanking sequences, further improving 
the specificity of the antibody. The mutations are indicated by ‘.
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In addition to the IG-MYC breakpoint other genetic abnormalities have also been de-
scribed in BL. Mutation and/or deletion of TP53 is commonly described in both BL patients 
and cell lines.30,31 The most commonly reported numerical abnormalities are (partial) gain of 
the q-arm of chromosome 1 and gain of the whole chromosome 7.32-35 Although a patho-
genetic role in addition to MYC overexpression is suggested, the molecular targets in these 
regions still have to be identified.36-38 
MYC overexpression has a strong oncogenic potential
The biological hallmark of BL is a deregulated overexpression of MYC.14,15 This overexpres-
sion is mainly caused by the translocation event, juxtaposing MYC to one of the IG enhanc-
ers.39 In addition, negative regulatory sequences within MYC are often deleted or mutated, 
further enhancing MYC transcription40,41 and stability,42 and thus activity. The myc protein 
is a transcriptional regulator, which functions through heterodimerization with max.43 Myc 
regulates up to 15-20% of all genes in the human genome and over-expression of MYC 
has many biological consequences, most of which underline its oncogenic potential (Figure 
2).44-46 The most important consequence of MYC overexpression is increased proliferation, 
as myc enhances cell cycle progression by induction of CDK2 and CDK4 through CDC25A;47 
induction of Cyclin D and E;48 and down-regulation of p2149 and p27.50 To sustain this high 
proliferation rate, myc can regulate a number of metabolic pathways, of which induction 
of LDH-A is the best known target.51 Myc can also up-regulate genes involved in nucleotide 
and protein synthesis and iron metabolism.45,52 As tumor cells tend to persist in cell-cycle it 
is no surprise that myc inhibits genes that result in cell differentiation,53 as this requires the 
cell to exit the cell-cycle. In addition to the increased proliferation, overexpression of MYC 
induces genomic instability,54,55 which may result in additional oncogenic hits. This genomic 
instability is further enhanced by the immortalization of cells via hTERT, a direct target of 
myc, which permits the indefinite maintenance of telomeres.56 Finally, myc downregulates 
several adhesion molecules (e.g. LFA-1),57 extra-cellular matrix proteins58 and HLA59 which 
might enable BL to escape immune surveillance.
In contrast to these oncogenic effects of MYC overexpression, myc also induces apop-
tosis. The p53-dependant apoptotic pathway is triggered by myc targets CDC25A and 
p14ARF,60,61 whereas a p53-independent pathway is induced by LDH-A.51 It seems inevitable 
that additional molecular or genetic events occur to counteract these pathways, otherwise 
BL could not survive. As said, mutations and/or deletion of p53 are frequent in BL,31 leading 
to such a result. But many other genes in the p53 pathway (e.g. via homozygous deletion 
of p14ARF/p16INK)62 could result in a similar defect in the apoptosis pathway and in conse-









BL requires a specific treatment
Historically, treatment of BL consisted of monotherapy with cyclophosphamide63 or 
prolonged chemotherapeutic regimens with an induction, consolidation and maintenance 
phase, adapted from the earlier ALL-regimens.64 However such therapies resulted in rela-
tively low cure rates (CR rates less than 50% and only 10-20% of long-term survival). With 
the introduction of short duration, intensive multi-agent chemotherapy in the early 1980s, 
cure rates improved considerably.65 Such intensive chemotherapeutic regimens are thought 
to be most appropriate for BL, as they maintain effective serum drug concentrations for at 
least 48-72 hours. Since the proliferation rate is extremely high in BL, with doubling times 
around 24-48 hours, almost all tumor cells will have passed through the cell cycle in that 
period of time and consequently be affected by the cytostatic drugs. Furthermore, the risk 
of tumor repopulation between cycles and development of drug resistance, due to the very 
short doubling time, is kept as low as possible by keeping the intervals between chemo-










figure 2. The oncogenic potential of MYC overexpression.
MYC overexpression has a great oncogenic potential via a number of mechanisms.
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Current pediatric regimens according to the Société Française d’Oncologie Pédiatrique 
(SFOP), Berlin-Frankfurt-Münster (BFM) and Pediatric Oncology Group (POG) protocols yield 
2 year survival rates between 60-80% in high risk and even up to 100% in low-risk pediat-
ric BL patients (reviewed by C Patte).66 The application of these regimens in adult patients 
resulted in somewhat lower, but still very good survival.64 As the survival percentages are 
now that high, challenges lie within the field of new therapies that lower the significant 
toxicity of these aggressive treatment regimens without lowering the treatment results. 
a subset of DLBCL shows features of BL
DLBCL is a type of NHL closely related to BL, and the most common type of NHL seen 
in adult patients (30-40% of all NHL) as well as the second most common type in children 
(around 25% of all NHL). It shows clear clinical, morphological and biologic heterogeneity 
(many reviews).67-70 Efforts to subdivide DLBCL in different subgroups have had considerable 
success. Since the discovery by Alizadeh et al in 2000 that DLBCL can be categorized in clini-
cally relevant subtypes based on gene expression,71 subsequent researchers have discovered 
a number of molecular subtypes (of which the germinal center B-cell like (GCB) and the 
activated B-cell like (ABC) subtypes gained most support), each with its own prognosis.72,73 
Within the wide spectrum of DLBCL, a subset exists with characteristics of BL (Figure 
3). These so called “gray-zone” cases have always been a problem in lymphoma classifica-
tions, and it could not be decided whether they should have their own entity or should be 
considered a variant of either BL or DLBCL. In the Working Formulation74 and REAL clas-
sification75 these cases had their own (provisional) entity (small non-cleaved, non-Burkitt 
lymphoma and Burkitt-like lymphoma, respectively). However, these entities had a very 
poor reproducibility.76 Therefore, it was decided in the 2001 WHO classification to consider 
these cases as either DLBCL or a variant of BL (atypical BL). Atypical BL cases showed greater 
pleomorphism in nuclear size and shape, with fewer and less prominent nucleoli than BL, 
but required a growth fraction of nearly 100% and a proven or strong presumptive evi-
dence of a MYC translocation.18 All other cases were considered to be DLBCL, creating a 
somewhat artificial and debatable split. Although these criteria seem to be straightforward, 
the distinction was still hard to make in daily practice. This is problematic as the distinc-
tion between BL and DLBCL has more than semantic consequences. BL patients show only 
limited response to standard DLBCL therapy, i.e. R-CHOP, whereas DLBCL patients respond 
relatively successfully to this far less toxic regimen and therefore should not be routinely 
exposed to standard intensive BL therapy. 
Another group of BL-mimickers are progressed indolent lymphomas (e.g. follicular lym-
phoma (FL) and mantle cell lymphoma (MCL) cases) that have gained a MYC translocation 
during their progression.77,78 These cases also show a Burkitt-like morphology and a high 
growth fraction, mimicking BL. However, in addition to the breakpoint in or around MYC, 








1to be the primary oncogenic event. These “double-hit” lymphomas show a very aggres-
sive clinical course and often do not respond to therapy at all, resulting in a very poor 
outcome.79 
figure 3. Morphology and iHC of two “gray-zone” cases.
The upper case involves a 32 year old male patient, with a tumor in the ileocecal region. In 
the upper left figure a low power magnification (10x) of an H&E staining can be appreciated. It 
shows a cohesive growth pattern with a “starry-sky” appearance, which suggest the diagnosis of 
BL. Upon immunohistochemical analysis, the tumor also has a BL immunophenotype (CD10+, bcl2-, 
bcl6+) and harbors a MYC translocation, again suggesting the diagnosis of BL. However at a high 
power magnification (100x, oil immersion, upper right), the relatively large and heterogeneous nuclei 
contradict the diagnosis of BL and favor a diagnosis of DLBCL. 
The lower case involves a 36 year old female patient, with an abdominal tumor. At low power 
magnification (10x, lower left) a BL morphology can be appreciated with a cohesive growth pattern 
and a clear “starry-sky” appearance. The inlay in the lower left figure also shows the high percentage 
of Ki-67 positive cells. However, at a high power magnification (100x, oil immersion, lower right), 
the nuclei appear atypical. In addition the results of immunohistochemistry (CD10+, bcl2+, bcl6+) 
and FISH (both a MYC and a BCL2 translocation were identified) suggest an other diagnosis than 
BL. Up to recently such cases were diagnosed as DLBCL rather than BL. In the novel WHO classification 
published in 2008, such cases are designated as B-cell lymphoma unclassifiable, with intermediate 
features between DLBCL and BL (“double-hit lymphoma”) ; see chapter 6.
Chapter 1
20
sCoPE of THis THEsis
In this thesis we set out to determine a molecular profile for BL. In addition we searched 
for an answer whether the “gray-zone” cases with characteristics of both BL and DLBCL 
should be considered as BL, DLBCL or deserve their own diagnostic entity. 
In chapter 2 we describe the epidemiology and clinical presentation of BL in the Neth-
erlands. We show a bimodal age-distribution with a peak at the pediatric age and a steady 
increase after the age of 50. We also show a strong male preponderance, which is especially 
present in pediatric patients. A number of clinical differences is observed between pediatric 
and adult patients, suggesting that we might be looking at different diseases in children 
and adults. 
In chapter 3 we describe the definition of BL based on currently used techniques (mor-
phology, immunohistochemistry (IHC) and fluorescent insitu hybridization (FISH)). We show 
that classic BL and DLBCL cases can easily be recognized, but that problems arise in the 
gray-zone in between and that additional techniques are needed to decide whether these 
“gray-zone” cases should be considered as BL or DLBCL. 
In chapter 4 we used gene expression profiling from RNA gene expression arrays, to 
distinguish BL from DLBCL. We show that BL has a characteristic gene expression profile, 
which is identical to the profile of atypical BL. We also show that with this robust, high 
throughput technique a distinction between BL and DLBCL can be made in the majority 
of cases, but that a small subset of cases remains, for which it is hard to make a clear-cut 
decision. These discrepant BL cases represent the molecular gray-zone. 
In chapter 5 we compared the genetic profile of classic and atypical BL cases with the 
profile of these discrepant BL cases. We show that there are no major genetic differences 
between classic and atypical BL cases, but the discrepant cases differ greatly in their genetic 
make-up. We also demonstrate the effect of different genetic aberrations on the gene 
expression profile of BL. 
In chapter 6 we used karyotyping data from all BL patients described in literature and 
determined a (cyto)genetic profile for BL. We show that BL typically harbors an IG-MYC 
translocation, relatively few additional numerical aberrations and no additional transloca-
tion of either BCL2, BCL6 or CCND1. We then compared the profile of this core subset of BL 
with the profile of other B-NHL (mainly DLBCL) harboring a MYC translocation and groups 
of “gray-zone” cases, which all appeared to be more genetically complex. Based on these 
data we suggest that the “gray-zone” cases should not be considered as BL. 
In chapter 7 we present data on the clinico-pathological heterogeneity in a high-risk 
cohort of DLBCL patients, treated with a high-dose intensive chemotherapeutic regimen 
and autologous stem cell transplantation. We show that the distinction between GCB and 








1In chapter 8 the different chapters are summarized. The distinction  between BL and DL-
BCL is discussed in more detail and put in perspective of similar research projects performed 
in the same era. At the end a number of future perspectives are presented.
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